Tennessee is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Clinical Outcomes of the ALPS Proximal Humerus Plating System
NCT03328650
Recruiting
The purpose of this study is to document the performance and clinical outcomes of the A.L.P.S® Proximal Humerus Plating System. Specific Aims: * Conduct physical assessments measuring shoulder strength and range of motion, physician assessment of radiographs * Obtain patient-reported outcomes regarding pain level, function capabilities, and work/leisure restrictions * Document revisions, complications, and adverse events
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Vanderbilt Orthopaedics, Nashville, Tennessee
Conditions: Proximal Humeral Fracture
Register for Updates
An INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY to ASSESS the PERFORMANCE of the CORDIO HEARO SYSTEM
NCT06378632
Recruiting
Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/25/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Heart Failure
Register for Updates
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults with CD33 And/or FLT3 Blood Cancers Including AML/MDS
NCT06325748
Recruiting
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
03/25/2025
Locations: TriStar Bone Marrow Transplant, Nashville, Tennessee
Conditions: AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
Register for Updates
InfasurfAero™ Versus Sham Treatment in Preterm Newborns with RDS
NCT05960929
Recruiting
The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.
Gender:
ALL
Ages:
Between 29 weeks and 36 weeks
Trial Updated:
03/25/2025
Locations: Western TN- Jackson-Madison County General Hospital, Jackson, Tennessee
Conditions: Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
Register for Updates
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT05629208
Recruiting
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Cutaneous Lupus Erythematosus (CLE)
Register for Updates
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
NCT05547165
Recruiting
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways... Read More
Gender:
ALL
Ages:
Between 7 days and 32 days
Trial Updated:
03/25/2025
Locations: Le Bonheur Children's Medical Center, Memphis, Tennessee
Conditions: Ductus Arteriosus, Patent
Register for Updates
Behavioral Economic and Wellness-based Approaches for Reducing Alcohol Use and Consequences Among Emerging Adults
NCT04776278
Recruiting
The purpose of this study is to evaluate an intervention approach for non-student emerging adults that attempts to reduce alcohol use by decreasing stress and increasing engagement in positive and goal-directed activities that provide meaningful alternatives to alcohol use.
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
03/25/2025
Locations: University of Memphis, Memphis, Tennessee
Conditions: Alcohol Abuse
Register for Updates
American Lung Association (ALA) Lung Health Cohort
NCT04543461
Recruiting
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Gender:
ALL
Ages:
Between 25 years and 35 years
Trial Updated:
03/25/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Lung Diseases
Register for Updates
Treating Young Adult Generalized Anxiety Disorder with Text-Message Delivered Cognitive Behavioral Therapy
NCT06774573
Recruiting
The purpose of the proposed study is to test the feasibility and efficacy of a "anxiety-focused" text-delivered counseling program to reduce anxiety symptoms among young adults (18-25) with elevated anxiety symptoms. We are primarily interested in whether the intervention will reduce anxiety. We have adapted an effective in-person, manualized cognitive behavioral therapy treatment for anxiety (Muñoz et al, 2000) into an 8-week, text-delivered anxiety treatment, named CBT-txt-Anxiety. We will tes... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
03/24/2025
Locations: University of Tennessee-Knoxville, Knoxville, Tennessee
Conditions: Generalized Anxiety Disorder
Register for Updates
Gene Editing For Sickle Cell Disease
NCT06506461
Recruiting
This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoieti... Read More
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
03/24/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Cystic Fibrosis
Register for Updates
Bio-Integrative, Fiber-Reinforced Kneebar for Treating Subchondral Insufficiency of the Knee
NCT06423378
Recruiting
The OSSIOfiber® Trimmable Fixation Nails are indicated for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis and bone grafts in the presence of appropriate additional immobilization (e.g., rigid fixation implants, cast, brace). Our hypothesis is that the use of OSSIOfiber® Trimmable Fixation Nails for treating subchondral insufficiency of the knee will result in improvement of patient-reported outcomes and imaging findings. The primary objective of this study is t... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Subchondral Insufficiency Fracture
Register for Updates